Uploaded November 2025 | Updated September 2026, 2 weeks ago
You can view the presentation slides here:
files.wearesrna.org/symposia/2025_rnds/slides/2025RNDS-Upcoming_therapies_NMOSD-Spencer_Hutto.pdf
files.wearesrna.org/symposia/2025_rnds/slides/2025RNDS-Upcoming_therapies_MOGAD-Grace_Gombolay.pdf
During this discussion at the 2025 RNDS, Dr. Spencer Hutto reviewed how NMOSD operates and what long term treatment strategies are available. Beginning with a summary of NMOSD before passing the baton to Dr. Grace Gombolay and answering audience questions, Dr. Hutto described complement inhibitors that target IL-6 and B-cell depleters. Acute treatments like IV steroids and plasmapheresis were also discussed. When considering a long-term maintenance treatment, Dr. Hutto recommended considering medication efficacy, the logistics of how it is delivered and how frequently, potential risks of the medication, and whether certain vaccinations are required to take the medication.
These long-term treatments include Rituxamab, which is not FDA-approved but has been used historically to target B cells, Inebilizimab, which has been FDA-approved to target an even wider range of B cells. They also include IL-6 antagonists such as Satralizumab, a subcutaneous medication that is also approved for pediatric patients older than 12 and complement inhibitors like Eculizumab and Ravilizumab. He then shifted to discuss current clinical trials, such as trials to extend these medications to be approved for a greater range of pediatric patients, a double-blind study comparing Rituxamab to the other four FDA-approved medications, and a study on Efgartigimod, a new acute medication that works similarly to plasmapheresis.
Dr. Grace Gombolay then took the stage, providing a summary of how MOGAD operates before launching into how MOGAD, which currently has no FDA-approved medication, is being treated. She shared information on ongoing clinical trials, such as COSMOG / Rozanolixizumab, which is currently a double-blind study with an open label extension for MOG-ab positive patients. This medication operates by binding the neonatal FC receptor, and similarly to plasma exchange, this medication clears MOG antibodies. She also covered the METEROID study, which is testing Satralizumab, which targets IL-6 to treat MOGAD in addition to NMOSD. There is also a treatment called CAR T-cell therapy, which works by removing the T-cells from a patient and changing what they are targeting to refocus on the MOGAD cells.
You can view the presentation slides here:
files.wearesrna.org/symposia/2025_rnds/slides/2025RNDS-Upcoming_therapies_NMOSD-Spencer_Hutto.pdf
files.wearesrna.org/symposia/2025_rnds/slides/2025RNDS-Upcoming_therapies_MOGAD-Grace_Gombolay.pdf
During this discussion at the 2025 RNDS, Dr. Spencer Hutto reviewed how NMOSD operates and what long term treatment strategies are available. Beginning with a summary of NMOSD before passing the baton to Dr. Grace Gombolay and answering audience questions, Dr. Hutto described complement inhibitors that target IL-6 and B-cell depleters. Acute treatments like IV steroids and plasmapheresis were also discussed. When considering a long-term maintenance treatment, Dr. Hutto recommended considering medication efficacy, the logistics of how it is delivered and how frequently, potential risks of the medication, and whether certain vaccinations are required to take the medication.
These long-term treatments include Rituxamab, which is not FDA-approved but has been used historically to target B cells, Inebilizimab, which has been FDA-approved to target an even wider range of B cells. They also include IL-6 antagonists such as Satralizumab, a subcutaneous medication that is also approved for pediatric patients older than 12 and complement inhibitors like Eculizumab and Ravilizumab. He then shifted to discuss current clinical trials, such as trials to extend these medications to be approved for a greater range of pediatric patients, a double-blind study comparing Rituxamab to the other four FDA-approved medications, and a study on Efgartigimod, a new acute medication that works similarly to plasmapheresis.
Dr. Grace Gombolay then took the stage, providing a summary of how MOGAD operates before launching into how MOGAD, which currently has no FDA-approved medication, is being treated. She shared information on ongoing clinical trials, such as COSMOG / Rozanolixizumab, which is currently a double-blind study with an open label extension for MOG-ab positive patients. This medication operates by binding the neonatal FC receptor, and similarly to plasma exchange, this medication clears MOG antibodies. She also covered the METEROID study, which is testing Satralizumab, which targets IL-6 to treat MOGAD in addition to NMOSD. There is also a treatment called CAR T-cell therapy, which works by removing the T-cells from a patient and changing what they are targeting to refocus on the MOGAD cells.
